Transform your testing experience for IVD applications—just 2 simple user interactions per run and up to 8 hours of walk-away time.
Enhancing the picture of CMV control
Cytomegalovirus (CMV) is a leading cause of morbidity and mortality in transplant recipients. Severe CMV infection in high-risk patients may develop soon after transplantation and, without effective treatment, may lead to CMV syndrome, tissue invasive disease, and potential rejection or loss of the graft.
The cobas® CMV reliably monitors CMV infection and is proven to provide comparable and reproducible viral load results across different institutions to reliably spot CMV and help transplant patients thrive. You can realise the following benefits for your laboratory and clinicians.
Unite against CMV with the assurance your clinicians need in clinical decision-making without the need to manage the complexity of lab developed tests. Progress towards standardization has been made, but there is still opportunity for improvement.5 With the standardized, CE-IVD real-time cobas® CMV PCR viral load test to spot CMV, we can collectively help transplant patients thrive.
cobas® CMV for use on the cobas® 4800 System is approved in the EU (CE-IVD). It is not approved in the United States.
cobas® CMV for use on the cobas® 6800/8800 Systems is approved in the EU (CE-IVD) and the United States (US-IVD).